TCRR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jun 2023 @ 04:00):

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer...

Stats
今日成交量	3.75M
平均成交量	325 040
市值	58.11M
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.352
ATR14	$0.105 (7.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-01	Tang Kevin C	Sell	4 394 800	Common Stock
2023-06-01	Ubs Oncology Impact Fund L.p.	Sell	3 370 982	Common Stock
2023-06-01	Mpm Sunstates Fund, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Mpm Bioventures 2014, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Gadicke Ansbert	Sell	3 370 982	Common Stock

INSIDER POWER
-89.65
Last 99 transactions
Buy: 1 629 400 \| Sell: 23 030 678

音量相关性

長: 0.06 (neutral)

短: -0.70 (moderate negative)

Signal:(27.338) Neutral

TCR2 Therapeutics Inc 相关性

10 最正相关
ROAD	0.928
STLD	0.926
RAIL	0.918
HEES	0.911
EQRR	0.906
FTXN	0.903
DXPE	0.9
PIE	0.896
THRN	0.895
ATOS	0.895

10 最负相关
BOCH	-0.936
BNIXU	-0.929
RGC	-0.919
ISPC	-0.897
MMAC	-0.891
ACXP	-0.885
HCDIP	-0.883
TSP	-0.876
NETE	-0.87
ORPH	-0.867

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

TCR2 Therapeutics Inc 相关性 - 货币/商品

0.32
( neutral )

0.73
( moderate )

0.00
( neutral )

0.25
( neutral )

-0.59
( weak negative )

-0.77
( moderate negative )

TCR2 Therapeutics Inc 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-3.93

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-3.93

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.57

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.40

Financial Reports:

No articles found.

TCR2 Therapeutics Inc

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

实时更新： TCR2 Therapeutics Inc [TCRR]

Upcoming Earnings Alert